Spectrum Pharmaceuticals — Neotherapeutics — Shareholder Meeting (June 2002)
66 slides from Spectrum Pharmaceuticals's shareholder meeting presentation, Jun 18, 2002
Slide 1: June 17, 2002
June 17, 2002
Slide 2: Presenters: Glasky, Shrotriya, Gulko
Alvin J. Glasky, Ph.D. Chairman, Chief Executive Officer, Chief Scientific Officer Rajesh C. Shrotriya, M.D. President, Chief Operating Officer Sam Gulko Senior Vice President of Finance, Chief Financial Officer
Slide 3: Forward-looking statements
This presentation contains forward-looking statements regarding future events and the future performance of NeoTherapeutics that involve risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, the early stage of product development,
Slide 4: 2001 Annual Stockholders Meeting
2001 Annual Stockholders Meeting Where are we? Where are we going? How will we get there?
Slide 5: Financial Update
Sam Gulko Senior Vice President of Finance, Chief Financial Officer, Secretary and Treasurer Financial Update
Slide 6: Income Statement Data, Fiscal Year
Income Statement Data Fiscal year ended December 31: (in thousands except per share data) 2001 2000 1999 Revenues $ 41 $ -- $ -- Operating Expenses Research & Development $ 20,611 $ 38,767 $ 20,058 General and Administrative $ 7,580 $ 5,107 $ 5,924 Loss From Operations $ (28,150) $ (43,874) $ (25,98
Slide 7: Income Statement Data, Three Months Ended March 31
Income Statement Data Three months ended March 31: (in thousands except per share data) 2002 2001 2000 Revenues $ 20 $ -- $ -- Operating Expenses Research & Development $ 4,924 $ 3,807 $ 8,500 General and Administrative $ 1,479 $ 1,801 $ 955 Loss From Operations $ (6,383) $ (5,608) $ (9,455) Other I
Slide 8: Balance Sheet
Balance Sheet (in thousands) 3/31/02 12/31/01 Cash and Marketable $ 5,812 $ 7,157 Securities Working Capital $ 2,128 $ 2,805 Total Assets $ 10,923 $ 12,825 Total Liabilities $ 4,560 $ 6,038 Minority Interest In Consolidated Subsidiaries $ - $ - Shareholder's Equity $ 6,362 $ 6,787
Slide 9: 2002 Financings
2002 Financings March, 2002 Common Stock with Warrants $ 6.2 million June, 2002 Common Stock with Warrants $ 1.7 million Total $ 7.9 million
Slide 10: Fully Diluted Common Shares
Fully Diluted Common Shares June 14, 2001 Issued and Outstanding (50,000,000 Authorized) 33,647,434 Investor Warrants, Stock Options, etc. 8,553,340 Potential total fully diluted common shares 42,200,774
Slide 11: Actual and Projected Burn Rate
2000 2001 1Q-2002 Q2-2002 Q3-2002 Q4-2002 Burn Rate 4.1 2.3 2.1 1.6 0.9 0.9 Actual and Projected Burn Rate Burn Rate in $ Millions Projected Actual
Slide 12: NeoTherapeutics' Technology Assets
Alvin J. Glasky, Ph.D. Chairman, Chief Executive Officer, Chief Scientific Officer Rajesh C. Shrotriya, M.D. President, Chief Operating Officer NeoTherapeutics' Technology Assets
Slide 13: NeoTherapeutics' Technology Assets
NeoTherapeutics' Technology Assets Solid Technology Foundation Neurology Functional Genomics Generics (NeoJB) Oncology
Slide 14: Neurology Division
Discovers and Develops Novel Patented Drugs Neurology Division NEUROLOGY DIVISION
Slide 15: Neurology
Neurology Neotrofin(tm) Parkinson's Disease Spinal Cord Injury Chemotherapy-Induced Neuropathy
Slide 16: Neotrofin in Parkinson's Disease
Neotrofin in Parkinson's Disease
Slide 17: Neotrofin in Parkinson's Disease Study Design
Neotrofin in Parkinson's Disease Study Design Stable Parkinson's disease patients Double blind (24 Neotrofin, 6 Placebo) 2 weeks at 250 mg twice daily, then 2 weeks at 500 mg twice daily, then 8 weeks at 1,000 mg twice daily Follow-up for 4 weeks with no treatment
Slide 18: Neotrofin in Chemotherapy-Induced Neuropathy
Neotrofin in Chemotherapy- Induced Neuropathy
Slide 19: Neotrofin: Neuropathy Data
30 32 34 36 38 40 42 44 46 48 50 Day 17 Control Vincristine Vincristine +Neotrofin 30mg Sensory Nerve Conduction Rate (m/sec) Data Source: AACR-NCI-EORTC Poster Neotrofin has neuroprotective and neuroregenerative effects on sensory nerve conduction responses in chemo- induced neuropathy model in rat
Slide 20: Neurology
Neurology AIT-034 Dementia NEO-339 Attention Deficit Hyperactivity Disorder Mild Cognitive Impairment Neotrofin Parkinson's Disease Spinal Cord Injury Chemotherapy-Induced Neuropathy
Slide 21: NEO-339 in Attention Model
Neurology NEO-339 in Attention Model
Slide 22: Neurology Antipsychotic Platform
Neurology Neotrofin Parkinson's Disease Spinal Cord Injury Chemotherapy-Induced Neuropathy AIT-034 Dementia NEO-339 Attention Deficit Hyperactivity Disorder Mild Cognitive Impairment Antipsychotic Platform (AP Platform) Multiple Therapeutic Targets Schizophrenia Depression Parkinson's Disease Analge
Slide 23: Importance of Antipsychotic Drugs
Importance of Antipsychotic Drugs Market size in 2001: Sales = $7.7 Billion Antipsychotics are 2% of all global pharmaceutical sales Market grew 30% in 2001 Olanzapine (Zyprexa) $ 3.1 Billion Clozapine (Clozaril) $ 1.0 Billion Risperidone (Risperdal) $ 1.8 Billion Others (Haldol, Seroquel, etc.) $ 1
Slide 24: Neurology Antipsychotic Platform
Neurology Antipsychotic Platform Efficacy is based upon a therapeutic balance between dopamine and serotonin neurotransmitter systems without effecting other receptors.
Slide 25: Antipsychotic Platform: Neurotransmitter Balance
Side Effect Receptors Adenergic - ? Histaminergic - H1 Histaminergic - H3 Muscarinic - M1 Muscarinic - M2 Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Therapeutic Effect Receptors Dopam
Slide 26: Antipsychotic Platform: Neurotransmitter Balance
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dop
Slide 27: Antipsychotic Platform: Neurotransmitter Balance
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dop
Slide 28: Antipsychotic Platform: Neurotransmitter Balance
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dop
Slide 29: Antipsychotic Platform: Neurotransmitter Balance
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dop
Slide 30: Antipsychotic Platform: Neurotransmitter Balance
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dop
Slide 31: Antipsychotic Platform: Neurotransmitter Balance
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dop
Slide 32: Antipsychotic Platform: Neurotransmitter Balance
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dop
Slide 33: Antipsychotic Platform: Neurotransmitter Balance
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dop
Slide 34: Antipsychotic Platform: Neurotransmitter Balance
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dop
Slide 35: Antipsychotic Platform: Neurotransmitter Balance
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dop
Slide 36: Antipsychotic Platform: Neurotransmitter Balance
Neurology Antipsychotic Platform Therapeutic balance between neurotransmitter systems: Indication Schizophrenia Parkinson's Disease Depression Analgesia (Pain) Drugs Risperidone Clozapine Olanzapine NEO-392 NEO-356 NEO-376 Therapeutic Effect Receptors Dopamine - D2s Dopamine - D3 Dopamine - D4.2 Dop
Slide 37: NEO-376 Does Not Produce Memory Disruption
NEO-376 Does Not Produce Memory Disruption
Slide 38: Antipsychotic Technology Platform
Eight compounds evaluated Receptor binding profile different than marketed antipsychotics Minimal to no cognitive impairment Minimal side effects predicted Improved toxicology profile Antipsychotic Technology Platform
Slide 39: Antipsychotic Technology Platform
Antipsychotic Technology Platform These compounds represent a new generation of antipsychotic therapy
Slide 40: NeoGene Technologies: Functional Genomics
Functional Genomics Technology to Identify Targets for Drug Development NeoGene Technologies Slide 85
Slide 41: NeoGene Technologies, Inc. Highlights
NeoGene Technologies, Inc. Two Pfizer alliances in 2001: $300,000 Milestone payments so far in 2002: $250,000 Recent publications 4 (1 pending) Highlights Slide 87
Slide 42: NeoJB
Manufacturing and Development of Patented and Generic Drugs and Over-the-counter Products NeoJB Slide 89
Slide 43: NeoJB Products
NeoJB Ciprofloxacin broad spectrum antimicrobial Ofloxacin broad spectrum antimicrobial Fluconazole antifungal Slide 91
Slide 44: NeoJB
NeoJB NeoJB is pursuing regulatory development of established products from India-based manufacturing sites Minimal financial resources are required at this time to further these efforts Slide 93
Slide 45: NeoOncoRx
Development and Commercialization of Late-Stage Anti-Cancer Drugs NeoOncoRx Slide 95
Slide 46: Oncology Products
Oncology Products Satraplatin Neoquin Elsamitrucin Slide 97
Slide 47: Elsamitrucin: Non-Hodgkin's Lymphoma
Elsamitrucin: Non-Hodgkin's Lymphoma Non-Hodgkin's Lymphoma 44,000 Phase 1 Phase 2 Phase 3 NDA New Cases/Year Source: UBS Warburg Estimated Market Size > $1 Billion Slide 99
Slide 48: Oncology Elsamitrucin Phase Trials
Oncology Elsamitrucin Phase 1 Slide 101 Phase 2 Trials completed Colorectal Ovarian Breast Lung Non-Hodgkins Lymphoma 3 trials completed
Slide 49: Elsamitrucin Phase 2 study
Data Source: Bristol Myers Squibb Non-Hodgkin's Lymphoma Phase 2 study in 31 refractory patients 60% of patients had failed two or more prior treatment regimens 25% of patients showed an objective response Improved side effect profile Oncology Elsamitrucin Slide 103
Slide 50: Neoquin: Bladder Cancer
Neoquin(tm) : Bladder Cancer Bladder Cancer 54,400 Phase 1 Phase 2 Phase 3 NDA New Cases/Year Source: Oncology, May 2000 Estimated Market Size > $300 Million Slide 105
Slide 51: Oncology Satraplatin
Oncology Satraplatin Slide 107
Slide 52: Satraplatin: Advantages
Satraplatin : Advantages Outpatient Hospital Home Convenience Short IV infusion Prolonged IV infusion Oral Administration - - +++ $$ Satraplatin ++ ++ Cross-resistance In-vitro +++ +++ Activity / Efficacy $600+ million $200 million Sales Carboplatin Cisplatin Slide 109
Slide 53: Satraplatin: Prostate Cancer
Satraplatin: Prostate Cancer In a 50 patient phase 3 study, satraplatin shows a survival advantage over the current therapy Prednisone + Satraplatin Prednisone Data Source: Bristol Myers Squibb Slide 111
Slide 54: NeoTherapeutics' Patents
NeoTherapeutics' Patents
Slide 55: NeoTherapeutics' U.S. Patent Status
NeoTherapeutics' U.S. Patent Status Issued Allowed Pending Total Neurology 9 1 16 26 Genomics 1 - 4 5 Oncology 6 - 1 7 (in-licensed) Corresponding foreign patents have been either issued or are pending
Slide 56: Summary of NeoTherapeutics' Technology Assets
Summary of NeoTherapeutics' Technology Assets Neotrofin(tm) - Parkinson's Disease Neotrofin(tm) - Chemotherapy-Induced Neuropathy Neotrofin(tm) - Spinal Cord Injury AIT-034 - Dementia NEO-339 - Attention Deficit Hyperactivity Disorder NEO-339 - Mild Cognitive Impairment AP Platform - Schizophrenia A
Slide 57: 2001 Annual Stockholders Meeting
2001 Annual Stockholders Meeting Where are we going? Where are we?
Slide 58: Where are we going?
Where are we going? Complete ongoing low-cost studies Parkinson's Disease Chemotherapy-Induced Neuropathy Spinal Cord Injury Out-licensing Co-development (partnership) Satraplatin clinical development (upon receipt of capital) Initiate phase 3 clinical trial in prostate cancer Initiate three phase 2
Slide 59: How will we get there?
2001 Annual Stockholders Meeting How will we get there? Where are we going? Where are we?
Slide 60: What are our strategic plans going forward?
What are our strategic plans going forward? Out-license products Co-development partnerships Cash financing through Investors Sale of divisions Merge the entire Company
Slide 61: Summary
Slide 64 Summary
Slide 62: It has been a tough quarter, but upside remains
It has been a tough quarter, but the upside potential of the NeoTherapeutics' portfolio remains...
Slide 63: It has been a tough quarter, but upside remains
It has been a tough quarter, but the upside potential of the NeoTherapeutics' portfolio remains... There is real value in our technology and product platforms
Slide 64: It has been a tough quarter, but upside remains
It has been a tough quarter, but the upside potential of the NeoTherapeutics' portfolio remains... There is real value in our technology and product platforms Our challenge is to gain realization and recognition of this value in the marketplace
Slide 65: It has been a tough quarter, but upside remains
It has been a tough quarter, but the upside potential of the NeoTherapeutics' portfolio remains... There is real value in our technology and product platforms Our challenge is to gain realization and recognition of this value in the marketplace
Slide 66: Slide
Slide 63